10-Q: Heron Therapeutics Boosts Liquidity, Acute Care Sales Soar

Heron Therapeutics reports strong acute care product sales growth and a significant debt refinancing, despite a one-time loss on debt extinguishment.

Summary

• Net product sales increased by 16.5% to $38.2 million for the three months ended September 30, 2025, compared to $32.8 million in the same period of 2024.
• Acute care net product sales (ZYNRELEF, APONVIE) surged by 67.2% to $12.3 million for the three months ended September 30, 2025, from $7.4 million in 2024.
• Oncology net product sales (CINVANTI, SUSTOL) saw a modest increase of 1.7% to $25.9 million for the three months ended September 30, 2025, from $25.4 million in 2024.
• The company reported a net loss of $17.5 million for the three months ended September 30, 2025, compared to a net loss of $4.8 million in the prior year, primarily due to a $11.3 million loss on debt extinguishment.
• Operating loss improved to $4.1 million for the three months ended September 30, 2025, from $4.5 million in the comparable 2024 period.
• Cash, cash equivalents, and short-term investments totaled $55.5 million as of September 30, 2025.
• Management believes current capital resources are sufficient to meet anticipated cash requirements for at least one year from the filing's issuance date.
• Successfully refinanced debt, including a new $150.0 million working capital facility extending maturity to September 1, 2030, and issued $35.0 million in 2031 convertible notes.
• Exchanged $150.0 million of 2026 Convertible Notes for a combination of common stock and cash, eliminating this near-term debt maturity.
• Completed a private placement equity offering, raising $27.7 million through common stock and Series A convertible preferred stock issuance.
• The company intends to wind down commercialization of SUSTOL over the next 12 months, with a potential reintroduction as early as late 2027.
• A U.S. District Court ruled in Heron's favor against Fresenius Kabi regarding CINVANTI patents, preventing generic approval before September 18, 2035.
• Settlement agreements were reached with Mylan and Qilu Pharmaceutical, granting licenses for generic CINVANTI and APONVIE starting June 1, 2032.
• A bench trial is scheduled for November 17, 2025, in the patent infringement case against Slayback Pharma LLC for CINVANTI.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company reported a higher net loss due to a one-time debt extinguishment, its operating loss significantly improved, and acute care product sales showed robust growth. The successful debt refinancing and equity raise have substantially improved liquidity and extended debt maturities. However, the declining oncology sales and ongoing patent litigations (despite some favorable outcomes) present continued challenges and uncertainties.

Positives

• Acute care product sales (ZYNRELEF and APONVIE) demonstrated significant growth, with ZYNRELEF sales increasing by 49.1% and APONVIE sales by 166.1% for the three months ended September 30, 2025, compared to the prior year.
• Operating loss decreased to $4.1 million for the three months ended September 30, 2025, from $4.5 million in the same period of 2024, indicating improved operational efficiency.
• Successfully refinanced and extended debt maturities, including a new $150.0 million working capital facility due September 1, 2030, and issued $35.0 million in 2031 convertible notes, significantly improving the company's liquidity profile.
• Eliminated $150.0 million of 2026 Convertible Notes through an exchange for common stock and cash, removing a near-term debt obligation.
• Raised $27.7 million in gross proceeds from a private placement equity offering, strengthening the balance sheet.
• A U.S. District Court ruled in the company's favor against Fresenius Kabi, upholding the validity of CINVANTI patents and preventing generic market entry until September 18, 2035.
• ZYNRELEF received FDA approval for an expanded indication in January 2024 and its Vial Access Needle (VAN) in September 2024, enhancing its market potential.
• CMS will provide separate Medicare reimbursement for ZYNRELEF in hospital outpatient and ambulatory surgical center settings from April 1, 2025, through December 31, 2027, under the NOPAIN Act, which is expected to drive adoption.
• APONVIE received CMS pass-through payment status effective April 1, 2023, supporting its commercialization.

Negatives

• Reported a higher net loss of $17.5 million for the three months ended September 30, 2025, compared to $4.8 million in the prior year, primarily due to a one-time $11.3 million loss on debt extinguishment.
• Cash used in operating activities increased to $18.4 million for the nine months ended September 30, 2025, from $10.7 million in the comparable 2024 period, indicating increased cash burn.
• Oncology net product sales for SUSTOL decreased by 30.9% for the three months and 32.4% for the nine months ended September 30, 2025, compared to the prior year.
• The company plans to wind down commercialization of SUSTOL over the next 12 months, which will incur one-time transition costs and remove a revenue stream.
• Oncology net product sales for CINVANTI decreased by 3.4% for the nine months ended September 30, 2025, primarily due to market competition from branded products and generics, a trend expected to continue.
• Gross profit margin for the three months ended September 30, 2025, slightly decreased to 68.8% from 71.2% in the prior year, partly due to increased inventory reserves and write-offs.

Risks

• Ability to successfully commercialize, market, and achieve market acceptance of ZYNRELEF, APONVIE, CINVANTI, and SUSTOL in the U.S. against competing products.
• Estimates regarding potential market opportunities for products and product candidates may prove wrong, impacting the ability to capture additional market share.
• The timing and outcome of pending patent litigations, including the appeal by Fresenius Kabi and the upcoming bench trial against Slayback Pharma LLC, could affect market exclusivity.
• Risk of being required to write-off additional inventory in the future if market conditions are less favorable than projected.
• Ability to establish satisfactory pricing and obtain adequate reimbursement from government and third-party payors for products.
• The impact of global economic and political developments, including geopolitical conflicts, inflation, and interest rate changes, on business and financial markets.
• Evolving legal and regulatory requirements and interpretations, including potential new tariffs or policies affecting the pharmaceutical industry, could increase costs or disrupt operations.
• Ability to retain, attract, and hire key personnel, which is crucial for continued operations and growth.
• The need to obtain additional financing and raise capital to fund operations or pursue business opportunities, as the company continues to incur operating losses and negative cash flows.
• Volatility and unpredictability of the stock market and credit market conditions, impacting the value of common stock and access to capital markets.
• Competition in the oncology market from branded products and generics is expected to continue to negatively impact CINVANTI and SUSTOL sales.

Future Outlook

Management believes that current cash, cash equivalents, and short-term investments will be sufficient to meet anticipated cash requirements for at least one year from the issuance of the condensed consolidated financial statements. The company intends to wind down commercialization of SUSTOL over the next 12 months while evaluating potential product updates, with a possible reintroduction as early as late 2027. Competition and decreases in oncology net product sales are expected to continue for the foreseeable future.

Management Comments

• Management believes that the Company's cash, cash equivalents and short-term investments will be sufficient to meet the Company's anticipated cash requirements for a period of at least one year from the issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
• We intend to wind down commercialization of SUSTOL over the next 12 months while we evaluate potential product updates. Subject to development progress, manufacturing readiness, and regulatory feedback, we may consider reintroducing SUSTOL as early as late 2027.
• During the SUSTOL wind down, we'll continue to support customers and manage inventory responsibly, and we expect one time transition costs, which we'll quantify as plans are finalized.

Industry Context

The biotechnology and pharmaceutical industry continues to face intense competition, particularly in established markets like oncology where generic entrants can quickly erode market share. Heron's strategy to focus on its growing acute care portfolio (ZYNRELEF, APONVIE) while re-evaluating its oncology product (SUSTOL) aligns with a trend of companies optimizing their product portfolios for higher-growth or less competitive segments. The NOPAIN Act's impact on ZYNRELEF reimbursement highlights a favorable regulatory environment for non-opioid pain management solutions, reflecting broader healthcare trends towards reducing opioid dependence. Patent litigations are a common and critical aspect of the pharmaceutical industry, with outcomes significantly impacting future revenue streams and competitive landscapes.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• U.S. District Court ruled in Heron's favor against Fresenius Kabi regarding CINVANTI patents (9,561,229 and 9,974,794), finding them valid and infringed, preventing generic approval before September 18, 2035. Fresenius Kabi filed an appeal on January 8, 2025, with briefing completed on September 24, 2025.
• Settlement agreement reached with Mylan on May 6, 2025, resolving patent litigation for generic versions of CINVANTI and APONVIE. Mylan was granted a license to market generic versions starting June 1, 2032.
• Ongoing patent infringement litigation against Slayback Pharma LLC (now Azurity Pharmaceuticals, Inc.) for CINVANTI patents. A bench trial is scheduled for November 17, 2025. The FDA may not approve Slayback's NDA until the earlier of June 12, 2026, or resolution of the litigation. The Patent Trial and Appeal Board discretionarily denied institution of Azurity's Post-Grant Reviews on August 14, 2025.
• Settlement agreement reached with Qilu Pharmaceutical (Hainan) Co., Ltd and Qilu Pharma, Inc. to resolve patent litigation for generic versions of CINVANTI and APONVIE. A Stipulation and Order of Dismissal was filed on November 3, 2025.

Related Party Transactions

• The 2026 Convertible Notes exchange and the 2031 Convertible Notes issuance involved funds affiliated with Baker Bros. Advisors LP and Rubric Capital Management LP, respectively. These are significant investors and may be considered related parties.

Stakeholder Impact

• **Shareholders**: The private placement equity offering and conversion of preferred stock will lead to dilution. The debt refinancing improves the company's financial stability by extending maturities, but the one-time debt extinguishment loss impacted net income. Favorable patent litigation outcomes protect future revenue streams for CINVANTI, while settlements with Mylan and Qilu provide clarity on generic entry dates.
• **Employees**: The decision to wind down SUSTOL commercialization may impact employees involved in that product line, though the filing does not specify details. The new office lease in Cary, North Carolina, suggests a potential shift or expansion of operational footprint.
• **Customers**: Continued availability and expanded indications for ZYNRELEF and APONVIE, along with CMS reimbursement, should benefit healthcare providers and patients. The wind-down of SUSTOL will require customers to transition to alternative treatments or await a potential reintroduction.
• **Creditors**: The debt refinancing significantly extends maturities and improves the company's ability to meet its obligations, reducing immediate financial risk for lenders.

Next Steps

• Continue to vigorously enforce intellectual property rights relating to CINVANTI, including awaiting oral argument for Fresenius Kabi's appeal and proceeding with the bench trial against Slayback Pharma LLC.
• Wind down commercialization of SUSTOL over the next 12 months and evaluate potential product updates for a possible reintroduction as early as late 2027.
• Quantify and manage one-time transition costs associated with the SUSTOL wind-down.
• Negotiate and execute a new manufacturing and supply agreement for future product supply by December 31, 2026.
• Continue to commercialize, market, and achieve market acceptance of ZYNRELEF, APONVIE, and CINVANTI in the U.S.
• Monitor and comply with postmarketing study requirements and standard postmarketing requirements for products.

Key Dates

Recommendation

Heron Therapeutics presents a mixed financial picture. The strong growth in acute care products (ZYNRELEF and APONVIE), coupled with favorable regulatory and reimbursement developments, indicates a positive trajectory for these key assets. The successful debt refinancing and equity raise have significantly improved the company's liquidity and extended debt maturities, addressing immediate financial concerns. However, the oncology portfolio, particularly SUSTOL, is underperforming, leading to a planned wind-down and associated costs. While the net loss for the nine-month period remained flat year-over-year, the one-time debt extinguishment loss masked an improvement in operating loss. The ongoing patent litigations, despite some favorable outcomes, introduce continued uncertainty. Given the strong performance of the acute care segment and improved financial flexibility, but balanced against the challenges in oncology and persistent operating cash burn, a 'hold' recommendation is appropriate. Investors should monitor the commercialization progress of ZYNRELEF and APONVIE, the impact of the SUSTOL wind-down, and the outcomes of remaining legal proceedings.

Keywords

Heron Therapeutics, HRTX, Biotechnology, Pharmaceuticals, ZYNRELEF, APONVIE, CINVANTI, SUSTOL, Pain Management, Postoperative Nausea and Vomiting, Chemotherapy-Induced Nausea and Vomiting, SEC Filing, 10-Q, Financial Results, Debt Refinancing, Patent Litigation, Commercialization, Acute Care, Oncology